Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - wegovy
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp0234c86891baf768298474181745e97d
identifier: http://ema.europa.eu/identifier
/EU/1/21/1608/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Wegovy 0.25 mg solution for injection in pre-filled pen
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-0234c86891baf768298474181745e97d
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/21/1608/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - wegovy
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What Wegovy is Wegovy is a medicine for weight loss and weight maintenance that contains the active substance semaglutide. It is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. It works by acting on targets (receptors) in the brain that control your appetite, causing you to feel fuller and less hungry and experience less craving for food. This will help you eat less food and reduce your body weight.
What Wegovy is used for Wegovy is used together with diet and physical activity for weight loss and to help keep the weight under control. It is used in adults, who have
BMI (Body Mass Index) is a measure of your weight in relation to your height.
Wegovy is used together with diet and physical activity for weight management in adolescents ages 12 years and above, who have
Do not use Wegovy
Warnings and precautions Talk to your doctor, pharmacist or nurse before using Wegovy.
The use of Wegovy is not recommended if you:
There is little experience with Wegovy in patients:
Please consult your doctor if one of the above applies to you.
Dehydration During treatment with Wegovy, you may feel sick (nausea) or be sick (vomiting), or have diarrhoea. These side effects can cause dehydration (loss of fluids). It is important that you drink enough fluids to prevent dehydration. This is especially important if you have kidney problems. Talk to your doctor if you have any questions or concerns.
Inflammation of the pancreas If you have severe and on-going pain in the stomach area (see section 4) see a doctor straight away as this could be a sign of inflamed pancreas (acute pancreatitis).
People with type 2 diabetes Wegovy cannot be used as a substitute for insulin. Do not use Wegovy in combination with other medicines that contain GLP-1 receptor agonists (such as liraglutide, dulaglutide, exenatide or lixisenatide).
Low blood sugar (hypoglycaemia) Taking a sulfonylurea or an insulin with Wegovy might increase the risk of getting low blood sugar levels (hypoglycaemia). Please see section 4 for the warning signs of low blood sugar levels. Your doctor may ask you to test your blood sugar levels. This will help your doctor decide if the dose of the sulfonylurea or insulin needs to be changed to reduce the risk of low blood sugar.
Diabetic eye disease (retinopathy) If you have diabetic eye disease and are using insulin, this medicine may lead to a worsening of your vision, and this may require treatment. Fast improvements in blood sugar control may lead to a temporary worsening of diabetic eye disease. If you have diabetic eye disease and experience eye problems while taking this medicine, talk to your doctor. Children and adolescents The safety and efficacy of Wegovy in children below 12 years of age have not been studied and are not recommended for use in this population.
Other medicines and Wegovy Tell your doctor, pharmacist or nurse if you are using, have recently used or might use any other medicines.
In particular, tell your doctor, pharmacist or nurse if you are using medicines containing the following:
Pregnancy and breast-feeding This medicine should not be used during pregnancy, as it is not known if it may affect your unborn child. Therefore, it is recommended to use contraception while using this medicine. If you wish to become pregnant, you should stop using this medicine at least two months in advance. If you become or are pregnant, think you may be pregnant or are planning to have a baby when using this medicine, talk to your doctor straight away, as your treatment will need to be stopped.
Do not use this medicine if you are breast-feeding, as it is unknown if it passes into breast milk.
Driving and using machines Wegovy is unlikely to affect your ability to drive and use machines. Some patients may feel dizzy when taking Wegovy mainly during the first 4 months of treatment (see section 4). If you feel dizzy be extra careful while driving or using machines. If you need any further information, talk to your doctor, pharmacist or nurse.
People with type 2 diabetes If you use this medicine in combination with a sulfonylurea or insulin, low blood sugar (hypoglycaemia) may occur which may reduce your ability to concentrate. Avoid driving or using machines if you get any signs of low blood sugar. See section 2, Warnings and precautions for information on increased risk of low blood sugar and section 4 for the warning signs of low blood sugar. Talk to your doctor for further information.
Wegovy contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium- free .
Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.
How much to use Adults The recommended dose is 2.4 mg once weekly. Your treatment will start at a low dose which will be gradually increased over 16 weeks of treatment.
Dose escalation Weekly dose Week 1 4 0.25 mg Week 5 8 0.5 mg Week 9 1 mg Week 13 1.7 mg From week 2.4 mg
Your doctor will assess your treatment on a regular basis.
Adolescents (above 12 years of age) For adolescents, the same dose escalation schedule as for adults should be applied (see above). The dose should be increased until 2.4 mg (maintenance dose) or maximum tolerated dose has been reached. Weekly doses higher than 2.4 mg are not recommended.
How Wegovy is given Wegovy is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle.
Detailed instructions on how to use the pen are on the other side of this leaflet.
People with type 2 diabetes Tell your doctor if you have type 2 diabetes. Your doctor may adjust the dose of your diabetes medicines to prevent you from getting low blood sugar.
When to use Wegovy
If necessary, you can change the day of your weekly injection of this medicine as long as it has been at least 3 days since your last injection. After selecting a new dosing day, continue with once a week dosing.
If you use more Wegovy than you should Talk to your doctor straight away. You may get side effects such as feeling sick (nausea), being sick (vomiting) or have diarrhoea, which may cause dehydration (loss of fluids).
If you forget to use Wegovy If you forgot to inject a dose and:
If you stop using Wegovy Do not stop using this medicine without talking to your doctor.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Other side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
The warning signs of low blood sugar may come on suddenly. They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking.
Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs. Low blood sugar is more likely to happen if you also take a sulfonylurea or insulin. Your doctor may reduce your dose of these medicines before you start using this medicine.
Uncommon (may affect up to 1 in 100 people)
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the pen label and carton after EXP . The expiry date refers to the last day of that month.
Store in a refrigerator (2 C 8 C). Do not freeze. Keep away from the cooling element. Always store the pen in the original carton in order to protect from light. Wegovy may be stored unrefrigerated for up to 28 days at a temperature not above 30 C.
Discard the pen if it has been exposed to light or temperatures above 30 C, has been out of the refrigerator for more than 28 days, or has been frozen.
Do not use this medicine if you notice that the solution is not clear and colourless.
After use: The pen is for single use and contains one dose only. Discard pen after use.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Wegovy contains
The active substance is semaglutide. Wegovy 0.25 mg solution for injection Each pre-filled pen contains 0.25 mg semaglutide in 0.5 mL (0.5 mg/mL).
Wegovy 0.5 mg solution for injection Each pre-filled pen contains 0.5 mg semaglutide in 0.5 mL (1 mg/mL).
Wegovy 1 mg solution for injection Each pre-filled pen contains 1 mg semaglutide in 0.5 mL (2 mg/mL).
Wegovy 1.7 mg solution for injection Each pre-filled pen contains 1.7 mg semaglutide in 0.75 mL (2.27 mg/mL).
Wegovy 2.4 mg solution for injection Each pre-filled pen contains 2.4 mg of semaglutide in 0.75 mL (3.2 mg/mL).
The other ingredients are disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide (for pH adjustment), water for injections. See also section 2 Wegovy contains sodium for information on sodium.
What Wegovy looks like and contents of the pack Wegovy is a clear and colourless solution for injection in a pre-filled disposable pen.
Each pen contains one dose only.
Pack size of 4 pre-filled pens.
Marketing Authorisation Holder and Manufacturer Novo Nordisk A/S Novo All
DK-2880 Bagsv rd Denmark
This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-0234c86891baf768298474181745e97d
Resource Composition:
Generated Narrative: Composition composition-en-0234c86891baf768298474181745e97d
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1608/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - wegovy
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp0234c86891baf768298474181745e97d
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp0234c86891baf768298474181745e97d
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1608/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Wegovy 0.25 mg solution for injection in pre-filled pen
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en